Overview

Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that covalently binds HER1, HER2, and HER4, producing prolonged pathway suppression. It is principally used in the extended adjuvant setting for early HER2-positive breast cancer, where the goal is to suppress late recurrence that may emerge after trastuzumab-based therapy ends. The 40 mg tablet fills a niche for distributors supporting long-duration adjuvant programs and for centers managing years-long treatment continuity for cured-intent patients. The covalent mode of binding means a single daily dose sustains suppression across the full dosing interval, supporting the year-long adjuvant commitment.

How It Works

Unlike reversible inhibitors, neratinib forms a covalent bond with the HER kinase domain, sustaining blockade of HER1/2/4 autophosphorylation and the downstream MAPK and PI3K–AKT axes. This durability is valuable against residual dormant cells that can reawaken years later. The irreversible binding also limits the rapid kinase recovery seen with some reversible agents, a mechanism relevant to overcoming acquired resistance and to maintaining pressure on the HER network throughout an extended adjuvant course. By covering HER1, HER2, and HER4 together, it attacks the receptor network from several angles rather than relying on a single node to stay blocked.

Indications

Neratinib is indicated as extended adjuvant treatment of early-stage HER2-positive breast cancer following trastuzumab-based therapy. It is also used with capecitabine in metastatic HER2-positive breast cancer previously treated with two or more regimens. Selection follows confirmed HER2 positivity, and the adjuvant indication specifically targets risk reduction after completion of prior anti-HER2 therapy. This extended adjuvant use specifically addresses the late recurrence window beyond the period covered by trastuzumab, a distinct niche for long-course supply.

Dosage & Administration

Extended adjuvant use is 240 mg daily for one year, built from 40 mg tablets, with loperamide prophylaxis to manage diarrhea. Dose holds follow gastrointestinal and hepatic tolerability, and the full-year course requires adherence support from the treating team.

Storage & Sourcing

Tablets ship in moisture-protective blisters with secondary cold-chain packaging. GIVE LIFE TIME International supplies batch certificates and export paperwork for cross-border B2B orders.

FAQ

Q: What does irreversible inhibition mean here? A: Neratinib forms a covalent bond with HER kinases, giving longer-lasting blockade than reversible agents.

Q: Why use it after trastuzumab ends? A: Extended adjuvant therapy targets late HER2 recurrence that can appear years after initial treatment.

Q: How is diarrhea managed? A: Prophylactic loperamide during the early weeks and dose holds per the management plan reduce severity.